Nutriband Inc
NTRB
Company Profile
Business description
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Contact
121 South Orange Avenue
Suite 1500
OrlandoFL32801
USAT: +1 407 377-6695
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 January 2026
Employees
3
Stocks News & Analysis
stocks
Materially undervalued ASX tech share
Long reinvestment runway supports our thesis on ASX technology company.
stocks
For US software stocks, it’s been an AI bust, not a boom
Once-hot software names are lagging. Are they good buys?
stocks
Finding value in the Aussie mining sector
Is the mining sector overvalued? A new Morningstar report highlights pockets of value that remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,800.80 | 42.60 | -0.48% |
| CAC 40 | 7,959.67 | 22.98 | -0.29% |
| DAX 40 | 23,239.18 | 147.31 | 0.64% |
| Dow JONES (US) | 46,448.27 | 202.86 | 0.44% |
| FTSE 100 | 9,534.91 | 4.80 | -0.05% |
| HKSE | 26,007.33 | 290.83 | 1.13% |
| NASDAQ | 22,872.01 | 598.92 | 2.69% |
| Nikkei 225 | 49,007.83 | 381.95 | 0.79% |
| NZX 50 Index | 13,483.32 | 16.53 | -0.12% |
| S&P 500 | 6,705.12 | 102.13 | 1.55% |
| S&P/ASX 200 | 8,515.50 | 48.20 | -0.56% |
| SSE Composite Index | 3,869.23 | 32.47 | 0.85% |